B. Riley Issues Optimistic Estimate for InfuSystem Earnings

Key Points

• B. Riley has raised its Q2 2026 earnings per share estimate for InfuSystem to $0.10, up from a previous forecast of $0.06, maintaining a "Strong-Buy" rating on the stock.
• The consensus estimate for InfuSystem's full-year earnings is $0.15 per share, with B. Riley also projecting Q4 2026 earnings at $0.16 EPS.
• Institutional investors have shown increased interest in InfuSystem, with notable increases in stock holdings by firms like BNP Paribas Financial Markets and Wells Fargo & Company in the fourth quarter.

InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) - Analysts at B. Riley increased their Q2 2026 earnings per share estimates for shares of InfuSystem in a report released on Tuesday, August 5th. B. Riley analyst A. Schock now anticipates that the company will earn $0.10 per share for the quarter, up from their previous estimate of $0.06. B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for InfuSystem's current full-year earnings is $0.15 per share. B. Riley also issued estimates for InfuSystem's Q4 2026 earnings at $0.16 EPS.

INFU has been the topic of several other research reports. Wall Street Zen downgraded InfuSystem from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 14th. Roth Capital began coverage on InfuSystem in a report on Tuesday, July 22nd. They issued a "buy" rating and a $12.00 price target for the company.

InfuSystem Stock Performance

INFU traded down $0.17 during midday trading on Thursday, reaching $8.67. The company's stock had a trading volume of 542,845 shares, compared to its average volume of 159,465. InfuSystem has a twelve month low of $4.61 and a twelve month high of $9.97. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. The company has a fifty day simple moving average of $6.11 and a 200 day simple moving average of $6.15. The stock has a market cap of $176.99 million, a P/E ratio of 142.94 and a beta of 1.81.

Hedge Funds Weigh In On InfuSystem

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its holdings in shares of InfuSystem by 67.9% during the 4th quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock worth $58,000 after purchasing an additional 2,768 shares during the period. Barclays PLC increased its stake in InfuSystem by 10.1% in the fourth quarter. Barclays PLC now owns 31,479 shares of the company's stock valued at $266,000 after purchasing an additional 2,882 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in InfuSystem by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock worth $78,000 after purchasing an additional 3,165 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in InfuSystem by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 95,471 shares of the company's stock valued at $514,000 after acquiring an additional 4,252 shares during the last quarter. Finally, CWM LLC increased its position in InfuSystem by 1,160.1% during the second quarter. CWM LLC now owns 4,826 shares of the company's stock worth $30,000 after acquiring an additional 4,443 shares during the period. Institutional investors own 71.13% of the company's stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.